Latest News - IQVIA
Top Corporates Hub
IQVIA
IQVIA (IQV): Buy, Sell, or Hold Post Q2 Earnings?
08.09.2026 14:31
The past six months have been a windfall for IQVIA’s shareholders. The company’s stock price has jumped 50%, hitting $267.77 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast
03.09.2026 18:10
Veeva raises its fiscal 2027 outlook as Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue and profitability.
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
03.09.2026 15:30
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This Healthcare Services Stock Has 37% Upside
13.08.2026 12:01
Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.
How Investors Are Reacting To IQVIA Holdings (IQV) Cardiac Gene Therapy Push And Higher 2026 Revenue Outlook
09.08.2026 15:11
In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA’s global clinical and commercialization infrastructure with Medera’s Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, alongside IQVIA’s second-quarter results, raised full-year 2026 revenue guidance to between US$17.28 billion and US$17.48 billion, and continued share repurchases. The partnership’s focus on AAV-based cardiac gene therapies and Novoheart’s...
IQVIA, Medera Partner to Accelerate Development of Cardiac Gene Therapies
06.08.2026 16:30
By Exec Edge Editorial Staff IQVIA (NYSE: IQV) and clinical-stage biopharmaceutical company Medera Inc. announced a strategic collaboration aimed at accelerating the development of cardiac gene therapies and human-based drug discovery platforms. Under the partnership, Medera’s Sardocor unit will use IQVIA’s clinical trial, regulatory and commercialization capabilities to advance FDA-cleared, first-in-human gene therapy programs targeting […] The post IQVIA, Medera Partner to Accelerate Developme
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
06.08.2026 15:29
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
FISV Q2 Earnings Miss Estimates on Margin Pressure, Revenues Decline
06.08.2026 15:19
Fiserv's Q2 revenues miss estimates and margin pressure leads to an earnings miss and cuts in its 2026 growth and profit outlook.
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
06.08.2026 14:47
Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.
Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
04.08.2026 16:33
IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.
Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
04.08.2026 15:58
IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.
The Backlog Tells the Real Story: Inside IQVIA’s Blowout Q2
04.08.2026 13:59
The global healthcare ecosystem in 2026 is leading to a strong recovery in clinical research, with global pharma R&D investment topping $250 billion and the clinical research organization (CRO) market rising to $72 billion at roughly a 9% annual pace. As biopharma companies move capital into complex biologic pipelines, AI-powered trial improvement, and practical data […]
1 Surging Stock with Exciting Potential and 2 Facing Challenges
04.08.2026 12:45
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
IQVIA: A Great Business At The Wrong Price (Rating Downgrade)
29.07.2026 09:59
IQVIA Holdings Inc. analysis: clinical trials & healthcare data leader. Key risksâslowing guidance, CSMS weakness, regulatory threats. Click for an IQV update.
IQVIA Holdings (IQV) Earnings Beat Keeps Fair Value In Focus
29.07.2026 09:07
IQVIA Holdings (IQV) stock moved after the company reported second quarter results that exceeded analyst estimates, raised full year 2026 revenue and earnings guidance, and expanded its share repurchase program, which highlighted management’s confidence in the business. See our latest analysis for IQVIA Holdings. The earnings beat and guidance raise have come on top of strong recent momentum, with a 90 day share price return of 55.07% and a 1 year total shareholder return of 24.87% suggesting...
US Stock Market Today: S&P 500 Futures Slip As Fed Rate Uncertainty Builds
29.07.2026 08:09
The Morning Bull - US Market Morning Update Wednesday, Jul, 29 2026 US stock futures are mixed in early Tuesday trade, with broad S&P 500 contracts slightly in the red while Dow futures edge up. The key driver is the US 10 year Treasury yield hovering around 4.64% as investors brace for this week’s Federal Reserve decision. Markets see roughly a one in three chance of a rate hike now and about a 56% chance by September. At the same time, US durable goods orders for June rose 0.3% and a core...
IQVIA (IQV) Shares Skyrocket, What You Need To Know
29.07.2026 03:33
Shares of clinical research company IQVIA (NYSE: IQV) jumped 12.9% in the morning session after the company reported second-quarter results that surpassed Wall Street's expectations and raised its full-year guidance. The company posted revenue of $4.37 billion, an 8.7% increase year-over-year, which beat estimates of $4.30 billion. Its adjusted earnings per share came in at $3.15, up 12.1% from the previous year and topping the consensus estimate of $3.03.
IQVIA Holdings (IQV) Soars on Revenue Growth Outlook, Strong Q2
29.07.2026 02:55
IQVIA Holdings Inc. (NYSE:IQV) extended its winning streak to a 4th straight session on Tuesday, jumping 13.94 percent to finish at $242.94 apiece after its higher revenue growth outlook and strong second-quarter performance reinforced investor confidence in its growth trajectory. In an updated report, the healthcare technology company said that it was able to grow […]
IQVIA (IQV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
29.07.2026 01:30
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.